Sugi Predict

Sugi Predict / Compounds / SCHEMBL496366

SCHEMBL496366

SCHEMBL496366

CCCCCN1CC[C@H](Nc2cc(C(F)(F)F)ccc2C(=O)Nc2ccc3c(c2)NC(=O)C3(C)C)C1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ UBE2M P61081 7/20 0.39
▸ DCUN1D1 Q96GG9 7/20 0.39
▸ CCR2 P41597 3/20 0.38
▸ CNR2 P34972 2/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ SCN10A Q9Y5Y9 4/20 0.37
▸ SCN8A Q9UQD0 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SLC6A5 Q9Y345 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496204 0.93 UBE2M (0.43) UBE2MDCUN1D1CCR2SCN10ASCN8A
SCHEMBL496258 0.85 SCN10A (0.38) UBE2MDCUN1D1SCN10ASCN8AMEN1
SCHEMBL10129624 0.81 TRPV4 (0.40) SCN10ASCN8ATRPV1RXFP1
SCHEMBL10129642 0.80 FLT3 (0.47) SCN10ASCN8ATRPV1RXFP1
SCHEMBL10129645 0.80 FLT3 (0.47) SCN10ASCN8ATRPV1RXFP1
SCHEMBL496111 0.77 TRPV1 (0.39) SCN10ASCN8ATRPV1RXFP1
SCHEMBL496026 0.77 TRPV1 (0.39) SCN10ASCN8ATRPV1RXFP1
SCHEMBL496209 0.77 TRPV1 (0.39) SCN10ASCN8ATRPV1RXFP1
Hydrochloric Acid SCHEMBL496005 0.76 SCN8A (0.39) SCN10ASCN8ATRPV1RXFP1
SCHEMBL495747 0.76 SCN10A (0.40) SCN10ASCN8ATRPV1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 — — EP claimed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 — — US claimed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 — — US claimed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 — — EP claimed
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 — — EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 — — US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 — — US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 UBE2M 1830/4885DCUN1D1 712/4885CCR2 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.